An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.

Our findings suggest that PLK1 could be an attractive immunotherapeutic target antigen for cancer immunotherapy, and that similar strategies would be applicable for the optimisation of cancer vaccines for the treatment of numerous viral diseases and malignant tumours.